FDA Approves Medtronic's Talent Captivia System for TEVAR

November 1, 2010—Medtronic, Inc. (Minneapolis, MN) announced that the US Food and Drug Administration has approved the Talent thoracic stent graft with Captivia delivery system. The Talent Captivia system is indicated specifically for the endovascular repair of fusiform aneurysms and saccular aneurysms/penetrating ulcers of the descending thoracic aorta in patients having the appropriate anatomy. The Talent Captivia system is now available in the United States for clinical use in the endovascular repair of thoracic aortic aneurysms.

According to Medtronic, the Talent Captivia system features a tip-capture mechanism for controlled deployment and precise placement of the implantable medical device. In addition to tip capture, the Captivia delivery system features a hydrophilic coating to ease insertion into the femoral artery and navigation through the iliac arteries en route to the aorta. The Talent thoracic stent graft is also now available in longer lengths (up to 215 mm in total length).


“The Captivia delivery system's tip capture mechanism is designed to provide excellent control of the stent graft during deployment to ensure that blood flow isn't occluded into the nearby arteries,” commented Edward Y. Woo, MD. “This improvement to the delivery system also increases my confidence in the device's deployment accuracy.”